January 20, 2009 - Cambridge Research & Instrumentation (CRi) and VisEn Medical signed a non-exclusive agreement to enable CRi to distribute VisEn's proprietary portfolio of fluorescent imaging agents and labels in North America, in an effort to broaden the use of leading fluorescence in vivo imaging technologies, applications and standards in research and drug development.

CRi has a history of working in multi-spectral fluorescence in vivo imaging and fluorescence microscopy imaging systems, and reportedly has a significant customer base with a broad range of applications in life science research today. The distributor will bring in VisEn's fluorescent in vivo agents and labels to iCR’s Maestro multispectral fluorescence imaging system customers.

VisEn’s proprietary in vivo imaging agents and labels are designed to provide a robust and broad range of biologically-specific imaging readouts in vivo. VisEn now offers over 25 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways in vivo, with several more new agents expected for launch in 2009. Key research areas enabled by the VisEn agents include imaging disease progression and therapeutic response in real time in oncology, inflammation, cardiovascular disease, bone disease and pulmonary diseases, all in the context of the living animal.

VisEn’s agents and labels are designed to be compatible with a range of fluorescence imaging systems, including the CRi Maestro system with its powerful proprietary multispectral imaging technology. With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking pre-clinical research into clinical medicine.

For more information: www.visenmedical.com and www.cri-inc.com


Related Content

News | Radiology Business

July 9, 2024 — Bracco and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time July 09, 2024
arrow
News | Contrast Media

May 8, 2024 — Swedish biotech company Ascelia Pharma AB has announced that its liver imaging drug candidate, Orviglance ...

Time May 08, 2024
arrow
News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | Breast Imaging

March 8, 2024 — Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies ...

Time March 08, 2024
arrow
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
Feature | Contrast Media Injectors | By Christine Book

Contrast media injectors are used to inject contrast media or contrast agents to enhance the blood and perfusion in ...

Time January 17, 2024
arrow
News | Contrast Media

December 11, 2023 — Bracco Imaging S.p.A., an innovative world leader delivering end-to-end products and solutions ...

Time December 11, 2023
arrow
News | Interventional Radiology

November 3, 2023 — Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced ...

Time November 03, 2023
arrow
Subscribe Now